AMAG Pharmaceuticals (AMAG Pharmaceuticals) Gross-Profit-to-Asset % : 44.01% (As of Sep. 2020)

View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. AMAG Pharmaceuticals's annualized Gross Profit for the quarter that ended in Sep. 2020 was $319.1 Mil. AMAG Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2020 was $725.0 Mil. Therefore, AMAG Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2020 was 44.01%.

AMAG Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for AMAG Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Gross-Profit-to-Asset % Chart

AMAG Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

17.06

13.57

15.19

16.66

22.31

AMAG Pharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															25.20	21.01	22.94	18.83	44.01

Competitive Comparison of AMAG Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, AMAG Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AMAG Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where AMAG Pharmaceuticals's Gross-Profit-to-Asset % falls into.

AMAG Pharmaceuticals Gross-Profit-to-Asset % Calculation

AMAG Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2019 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2019 )	/	( (Total Assets (A: Dec. 2018 )	+	Total Assets (A: Dec. 2019 ))	/ count )
	=	219.353	/	( (1175.459	+	791.227)	/ 2 )
	=	219.353	/	983.343
	=	22.31 %

AMAG Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2020 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2020 )	/	( (Total Assets (Q: Jun. 2020 )	+	Total Assets (Q: Sep. 2020 ))	/ count )
	=	319.064	/	( (715.549	+	734.356)	/ 2 )
	=	319.064	/	724.9525
	=	44.01 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2020) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

AMAG Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.amagpharma.com

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Executives

Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano	officer: Chief Operating Officer	C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos	officer: Interim CFO	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson	director, 10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat	director
Davey Scoon	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers	director, officer: President & CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick	officer: Chief Human Resources Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022